Shapiro et al. report preliminary proof-of concept that in 17 people with type 1
diabetes, pancreatic endoderm cells in an investigational subcutaneous device (VC02) achieved engraftment and insulin expression in 63% of units at 3– 12 months post-implant. Pluripotent stem cells may be a scalable, renewable alternative to pancreatic islet transplants.
Check out the full article here